{"url_path":"/sec/ions/8-k/2026-06-12/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-025050-index.html","accession_number":"0001140361-26-025050","cik":"0000874015","ticker":"IONS","issuer_name":"IONIS PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-025050-index.html","primary_entity_key":"0000874015","primary_entity_name":"IONIS PHARMACEUTICALS INC"},"word_count":227,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\n \n\nOn June 12, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) shared positive new\ndata from the open-label extension study of CORE and CORE2 (“CORE-OLE”) evaluating olezarsen in people with severe hypertriglyceridemia (“sHTG”) during an oral presentation at the National Lipid Association Scientific Sessions in Chicago.  The presentation included new, longer-term hepatic magnetic resonance imaging-proton density fat fraction (“MRI-PDFF”) results from 53 patients who completed 12 months of treatment in the CORE-OLE, representing approximately 25% of patients enrolled in the MRI-PDFF substudy. The substudy enrolled a\nsubset of patients from CORE and CORE2 with elevated liver fat at baseline to evaluate hepatic fat fraction (“HFF”) over time by serial MRI assessments. During the CORE-OLE, all patients\nreceived the 80 mg dose of olezarsen. Key findings from the presentation include:\n\n•\n\nMean HFF levels returning toward baseline, after 24 months of treatment with the 80 mg dose of olezarsen.\n\n•\n\nMean changes in HFF levels were less pronounced in patients who transitioned from the 50 mg dose in the randomized, double-blind, placebo-controlled portion of the studies to the 80 mg dose in the CORE-OLE.\n\n•\n\nOlezarsen continued to demonstrate a favorable safety profile with longer-term treatment.\n\n•\n\nPatient retention in the CORE-OLE has been very high, with more than 90% of eligible patients who completed the CORE and CORE2 studies transitioning into and remaining in the CORE-OLE."}